Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CTX-009 |
Trade Name | |
Synonyms | CTX009|CTX 009|ES-104|ES104|ES 104|NOV1501|TR 009 |
Drug Descriptions |
CTX-009 is a bispecific antibody that targets DLL4 and VEGFA, which potentially inhibits tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P02-03). |
DrugClasses | DLL4 Antibody 7 VEGFA Antibody 4 |
CAS Registry Number | NA |
NCIT ID | C185865 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cisplatin + CTX-009 + Durvalumab + Gemcitabine | CTX-009 Cisplatin Durvalumab Gemcitabine | 0 | 1 |
CTX-009 | CTX-009 | 0 | 1 |
CTX-009 + Paclitaxel | CTX-009 Paclitaxel | 0 | 1 |